Tens Of Thousands Of Nevadans Rely On At Least One Of The Ten Medications That Medicare Announced It Will Begin Negotiating For Lower Prices
WASHINGTON, D.C. – Today, U.S. Senator Jacky Rosen (D-NV) applauded news that Medicare selected the first ten prescription drugs to begin negotiations for lower prices. Thanks to the Inflation Reduction Act that Senator Rosen helped pass, Medicare has the authority for the first time in history to negotiate prescription drug prices directly with pharmaceutical companies. The first ten medications selected for price negotiations are some of the most expensive and widely used by seniors. They include:
| Eliquis Jardiance Xarelto Januvia Farxiga | Entresto Enbrel Imbruvica Stelara NovoLog |
According to estimates, tens of thousands of Nevadans on Medicare Part D rely on one or more of these medications.
“As I’ve traveled across Nevada, I’ve met seniors who shared their stories about not being able to afford their medications and being forced to make tough decisions as a result,” dijo el Senador Rosen. “It was with their stories in mind that I proudly helped pass legislation to allow Medicare to negotiate for lower prescription drug prices. At a time when Nevadans are facing high prices and inflation, today’s announcement is an important step towards lowering costs and making prescription drugs more affordable.”
Senator Rosen has been a leader in fighting to lower costs for hardworking Nevadans. She helped secure several wins in the Inflation Reduction Act to help lower costs and put dollars back in the pockets of hard-working Nevadans including provisions to: lower health care premiums, lower prescription drug costs, ensure taxpayers and rural communities get fair returns on leases of public lands for oil and gas, and expand clean energy tax credits. She also supported the Empowering Medicare Seniors to Negotiate Drug Prices Act, which would allow Medicare to negotiate the best price of prescription drugs for seniors. Last Congress, Senator Rosen introduced the bipartisan Advancing Affordable Medicines for Families Act to examine the impact that nonprofit generic drug companies would have on lowering drug costs, addressing drug shortages, and accelerating the development of new drugs.
###
